Magellan Rx Management saw a significant shift in utilization from Janssen Biotech, Inc.’s Remicade (infliximab) to biosimilars after it implemented a comprehensive utilization management (UM) program, resulting in 34% drug cost savings, the PBM reported.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.